background
use
oral
ribavirin
rbv
respiratori
syncyti
viru
rsv
infect
well
studi
drastic
increas
cost
aerosol
rbv
aim
compar
outcom
hematopoiet
cell
transplant
hct
recipi
treat
oral
aerosol
rbv
rsv
infect
method
review
record
hct
recipi
rsv
infect
treat
oral
aerosol
rbv
septemb
april
immunodefici
score
index
isi
use
classifi
patient
low
moder
high
risk
progress
lower
respiratori
infect
lri
death
result
seventi
patient
receiv
aerosol
rbv
oral
rbv
group
rate
progress
lri
p
mortal
rate
significantli
differ
group
aerosol
oral
p
aerosol
oral
p
classif
regress
tree
analysi
identifi
isi
independ
predictor
mortal
patient
isi
mortal
significantli
increas
overal
yet
remain
similar
aerosol
oral
therapi
group
propens
score
adjust
cox
proport
hazard
model
show
similar
mortal
rate
oral
aerosol
therapi
group
hazard
ratio
hr
confid
interv
ci
p
conclus
hct
recipi
rsv
infect
similar
outcom
treat
aerosol
oral
rbv
oral
ribavirin
may
effect
altern
aerosol
rbv
potenti
signific
cost
save
respiratori
syncyti
viru
rsv
singlestrand
rna
viru
paramyxovirida
famili
common
caus
season
respiratori
viral
infect
although
rsv
infect
frequent
selflimit
caus
upper
respiratori
infect
uri
may
progress
sever
lower
respiratori
infect
lri
immunocompromis
patient
includ
hematopoiet
cell
transplant
hct
recipi
rsv
infect
hct
recipi
associ
substanti
morbid
mortal
often
complic
respiratori
failur
sever
risk
factor
progress
lri
andor
mortal
includ
myelosuppress
preengraft
earli
posttransplant
ie
within
day
age
mismatch
unrel
donor
ribavirin
rbv
guanosin
analogu
activ
rna
dna
virus
often
use
treat
rsv
infect
aerosol
rbv
approv
rsv
lri
pediatr
patient
although
frequent
use
offlabel
popul
data
rbv
treat
rsv
infect
hct
recipi
come
small
retrospect
studi
heterogen
treatment
combin
nevertheless
treatment
rbv
shown
prevent
poor
outcom
largest
evalu
rbv
therapi
rsv
hct
recipi
shah
et
al
show
aerosol
rbv
uri
stage
reduc
progress
lri
rsvassoci
mortal
compar
treatment
studi
rsv
treatment
evalu
aerosol
rbv
inform
formul
limit
aerosol
rbv
treat
rsv
remain
controversi
due
lack
random
control
trial
occup
exposur
concern
high
drug
cost
thu
immunodefici
score
index
isi
develop
identifi
patient
would
benefit
rbv
base
risk
progress
lri
rsvassoci
mortal
patient
high
isi
shown
highest
rate
progress
death
well
greatest
benefit
aerosol
rbv
administ
uri
stage
reduct
progress
mortal
respect
dramat
increas
cost
aerosol
rbv
limit
use
mani
institut
necessit
quest
altern
therapi
mainli
via
oral
rbv
addit
inexpens
oral
rbv
allow
outpati
therapi
data
use
oral
rbv
treat
rsv
hct
recipi
scarc
purpos
studi
compar
progress
lri
mortal
hct
recipi
rsv
infect
treat
either
oral
aerosol
rbv
review
record
hct
recipi
receiv
rbv
rsv
infect
septemb
april
univers
texa
md
anderson
cancer
center
biofir
filmarray
respiratori
panel
biofir
diagnost
salt
lake
citi
utah
use
diagnos
rsv
patient
age
year
histori
hct
includ
receiv
dose
rbv
rsv
infect
inpati
outpati
patient
exclud
enrol
clinic
trial
rsv
receiv
rbv
nonrsv
indic
formal
restrictionsreview
either
formul
rbv
place
time
studi
patient
identifi
access
pharmaci
record
rbv
ordersprescript
first
episod
rsv
infect
consid
patient
patient
classifi
aerosol
oral
rbv
group
receiv
formul
hour
initi
therapi
formul
switch
hour
classifi
formul
chang
uri
defin
signssymptom
rsv
infect
rhinorrhea
nasalsinu
congest
pharyng
cough
without
chest
radiograph
imag
suggest
pneumonia
lri
defin
respiratori
symptom
along
chest
radiograph
imag
suggest
lri
ie
ground
glass
opac
interstiti
infiltr
without
isol
rsv
lower
respiratori
sampl
rsv
consid
communityacquir
symptom
develop
hospit
within
day
admiss
nosocomi
symptom
develop
day
admiss
primari
outcom
allcaus
mortal
secondari
outcom
includ
progress
lri
patient
uri
upon
treatment
initi
allcaus
mortal
need
intens
care
unit
icu
admiss
mechan
ventil
risk
progress
lri
rsvassoci
death
stratifi
isi
tabl
follow
inform
collect
patient
demograph
includ
age
sex
raceethn
malign
hct
engraft
date
condit
regimen
graftvshost
diseas
gvhd
statu
immunosuppress
medic
within
day
prior
rsv
diagnosi
formul
durat
rbv
therapi
creatinin
clearanc
hemoglobin
respiratori
copathogen
radiograph
imag
result
icu
admiss
andor
mechan
intub
date
caus
death
studi
approv
md
anderson
institut
review
board
inform
consent
waiver
grant
categor
continu
variabl
compar
use
fisher
exact
test
wilcoxonrank
sum
test
respect
primari
outcom
mortal
assess
visual
use
kaplanmei
curv
multivari
cox
proport
hazard
final
multivari
cox
proport
hazard
model
incorpor
characterist
p
valu
bivari
analysi
administr
oral
rbv
forc
model
proport
hazard
assumpt
visual
assess
use
plot
scale
schoenfeld
residu
time
propens
scorebas
analysi
perform
also
control
confound
creat
propens
score
nonparsimoni
logist
regress
model
incorpor
measur
baselin
characterist
sex
race
transplant
type
isi
score
site
infect
time
transplant
gvhd
steroid
use
nosocomi
infect
statu
creat
model
probabl
oral
rbv
treatment
propens
score
use
gener
invers
probabl
treatment
weight
iptw
subsequ
iptw
cox
proport
hazard
model
progress
uri
lri
assess
among
patient
treat
uri
stage
use
finegray
compet
risk
model
treat
death
compet
risk
progress
lri
tradit
multivari
model
iptw
compet
risk
model
construct
progress
lri
mortal
assess
previous
publish
isi
risk
categori
identifi
singl
group
highest
risk
classif
regress
tree
cart
analysi
use
identifi
isi
score
predict
mortal
progress
lri
mortal
compar
cartidentifi
lowand
highrisk
patient
data
collect
use
redcap
electron
data
captur
tool
statist
analys
perform
use
stata
overal
isi
sum
weight
score
immunodefici
criteria
present
time
rsv
diagnosi
patient
isi
classifi
low
risk
moder
risk
high
risk
progress
lri
andor
rsvassoci
mortal
abbrevi
alc
absolut
lymphocyt
count
anc
absolut
neutrophil
count
gvhd
graftvshost
diseas
isi
immunodefici
viru
score
index
lri
lower
respiratori
infect
rsv
respiratori
syncyti
viru
uri
upper
respiratori
infect
hodgkin
lymphoma
nonhodgkin
lymphoma
multipl
myeloma
match
unrel
haploident
hct
rsv
infect
hct
rsv
infect
acut
gvhd
chronic
gvhd
corticosteroid
use
neutropenia
lymphopenia
b
hb
gdl
baselin
median
iqr
c
nosocomi
infect
consecut
rsv
season
adult
hct
recipi
microbiolog
document
rsv
infect
receiv
rbv
therapi
three
patient
exclud
transplant
done
outsid
institut
transplant
date
andor
condit
regimen
unknown
remain
patient
receiv
aerosol
receiv
oral
rbv
tabl
patient
oral
aerosol
rbv
receiv
altern
formul
hour
classifi
regimen
switch
group
similar
baselin
demograph
median
age
rsv
diagnosi
year
rang
year
multipl
myeloma
aml
common
underli
malign
median
time
hct
rsv
infect
day
rang
day
malign
relaps
time
rsv
infect
similar
group
aerosol
oral
p
lymphopenia
rsv
diagnosi
common
aerosol
oral
rbv
group
p
signific
differ
group
numbertyp
respiratori
copathogen
similar
group
supplementari
tabl
fiftysix
patient
uri
rsv
present
present
lri
cart
analysi
identifi
isi
signific
predictor
mortal
sensit
specif
area
receiv
oper
curv
found
among
patient
treat
aerosol
oral
rbv
patient
isi
similar
rate
progress
lri
vs
mortal
vs
mortal
vs
tabl
supplementari
tabl
patient
isi
higher
mortal
rate
isi
rate
remain
similar
group
mortal
aerosol
oral
mortal
aerosol
oral
patient
demograph
clinic
characterist
stratifi
mortal
present
tabl
outcom
shown
tabl
patient
die
within
day
like
receiv
corticosteroid
survivor
vs
p
lymphopenia
vs
p
nosocomi
infect
vs
p
highrisk
isi
score
vs
p
differ
note
percentag
patient
receiv
oral
rbv
initi
treatment
survivor
nonsurvivor
p
figur
supplementari
figur
complet
result
univari
multivari
cox
proport
hazard
model
depict
icu
transfer
rate
need
mechan
ventil
oral
vs
aerosol
rbv
patient
similar
icu
transfer
vs
p
mechan
ventil
vs
p
hemoglobin
level
similar
aerosol
oral
group
baselin
day
day
newonset
grade
anemia
classifi
common
terminolog
criteria
advers
event
supplementari
tabl
studi
hct
recipi
rsv
infect
similar
mortal
progress
lri
treat
aerosol
oral
rbv
despit
use
multipl
statist
method
includ
propens
scorebas
model
signal
increas
efficaci
aerosol
rbv
observ
moreov
oral
rbv
associ
increas
rate
grade
greater
anemia
find
suggest
oral
rbv
may
safe
effect
altern
aerosol
rbv
treatment
rsv
hct
recipi
import
implic
hct
program
given
signific
aerosol
rbv
cost
treatment
option
rsv
infect
hct
recipi
limit
rbv
commonli
use
pharmaceut
agent
market
formul
aerosol
oral
intraven
intraven
formul
approv
us
food
drug
administr
fda
routin
avail
clinic
use
although
aerosol
rbv
fdaapprov
treatment
rsv
children
sever
retrospect
studi
suggest
treatment
aerosol
rbv
associ
reduc
mortal
hct
recipi
thu
broadli
use
indic
due
teratogen
aerosol
rbv
must
administ
inpati
via
scaveng
tent
daili
administr
time
challeng
patient
provid
cost
aerosol
rbv
increas
roughli
per
day
place
cost
treatment
cours
stagger
result
aerosol
rbv
longer
viabl
mani
institut
leav
oral
rbv
avail
treatment
institut
aerosol
rbv
remain
unrestrict
given
widespread
public
increas
cost
therapi
eas
oral
administr
shift
use
toward
oral
rbv
occur
natur
last
rsv
season
howev
pauciti
data
oral
rbv
rsv
hct
recipi
limit
widespread
accept
equival
altern
aerosol
rbv
prior
studi
oral
rbv
hct
patient
provid
limit
mix
result
knowledg
largest
studi
date
compar
outcom
oral
aerosol
rbv
rsv
hct
recipi
thirtyday
mortal
rate
similar
group
mortal
significantli
lower
recipi
oral
rbv
transfer
icu
b
mechan
ventil
b
multivari
cox
proport
hazard
model
sever
signific
predictor
mortal
reflect
underli
highrisk
transplant
relaps
underli
malign
like
reflect
degre
residu
select
bia
rather
true
efficaci
signal
although
number
patient
high
risk
isi
rel
low
indic
increas
mortal
observ
patient
treat
oral
rbv
addit
mortal
oral
aerosol
rbv
patient
lri
suggest
oral
formul
effect
aerosol
therapi
lower
respiratori
diseas
patient
uri
similar
progress
rate
lri
regardless
treatment
oral
aerosol
rbv
find
robust
standard
finegray
compet
risk
model
propens
scorebas
analysi
mortal
patient
high
risk
progress
appear
addit
risk
treat
oral
rbv
find
contrast
casey
et
al
evalu
patient
treat
oral
rbv
rsv
infect
allogen
hct
uri
cohort
uri
progress
document
everi
case
patient
die
respiratori
failur
howev
patient
treat
median
day
follow
transplant
high
risk
progress
regardless
treatment
wherea
cohort
includ
entir
posttransplant
spectrum
studi
includ
compar
group
receiv
rbv
limit
data
compar
oral
rbv
therapi
fiftysix
patient
univers
heidelberg
treat
oral
rbv
rsv
outbreak
hct
recipi
receiv
oral
rbv
multivari
analysi
identifi
treatment
rbv
protect
factor
fatal
outcom
p
marcelin
institut
aerosol
rbv
commonli
dose
intermitt
g
hour
time
per
day
two
common
dose
strategi
oral
rbv
use
fix
dose
mg
everi
hour
load
dose
mgkg
follow
mgkgday
divid
dose
adjust
renal
dysfunct
dose
use
base
report
literatur
howev
optim
dose
rbv
rsv
establish
similarli
optim
durat
therapi
unknown
substanti
heterogen
practic
report
assess
optim
dose
durat
oral
rbv
area
ongo
research
group
strength
studi
includ
comparison
outcom
rbv
formul
diseas
sever
control
mani
cofound
addit
size
institut
inclus
consecut
rsv
season
allow
inclus
larg
number
patient
differ
hct
type
risk
strata
includ
relaps
diseas
howev
studi
limit
singlecent
studi
evalu
hct
recipi
therefor
generaliz
nontranspl
recipi
institut
may
limit
studi
includ
lowrisk
hct
patient
isi
may
requir
treatment
rbv
howev
group
compris
small
portion
cohort
similarli
number
patient
highrisk
group
isi
low
cohort
thu
impact
oral
rbv
highrisk
patient
need
studi
last
studi
retrospect
natur
significantli
patient
lymphopenia
aerosol
group
although
found
independ
associ
mortal
multivari
analysi
tabl
summari
studi
provid
evid
support
use
oral
rbv
place
aerosol
rbv
treatment
rsv
infect
hct
recipi
includ
patient
high
risk
progress
mortal
find
still
requir
valid
prefer
via
prospect
trial
mani
institut
alreadi
adopt
practic
find
may
address
remain
concern
use
oral
instead
aerosol
rbv
hct
patient
supplementari
materi
avail
clinic
infecti
diseas
onlin
consist
data
provid
author
benefit
reader
post
materi
copyedit
sole
respons
author
question
comment
address
correspond
author
